New Parkinson's Medication: FDA Approves Tavapadon (Juvmo) in 2026

For many people living with Parkinson's disease, the hardest part of treatment is the balancing act. A medication that steadies tremor and stiffness today may need to be raised next year, and higher doses can bring side effects. That is why the U.S. Food and Drug Administration's approval of a new Parkinson's medication this fall is worth knowing about, even if it is not the right fit for everyone.

What the FDA approved

On September 25, 2026, the FDA approved Juvmo (tavapadon) tablets "to treat Parkinson's disease in adults," according to the FDA's Novel Drug Approvals for 2026 list. The drug's maker, AbbVie, announced the approval on September 28 and said it expected the medicine to become available in the United States in October 2026 (AbbVie press release). Juvmo is now available in the U.S. through specialty pharmacies.

Tavapadon is taken by mouth once a day, with or without food. It can be used on its own or together with levodopa, the long-standing foundation of Parkinson's treatment. The FDA's prescribing information describes a gradual "titration" schedule, meaning the dose is built up step by step under a doctor's guidance.

Why it is different

Parkinson's motor symptoms appear when the brain loses many of the cells that make dopamine, a chemical messenger that helps control movement. Medicines called dopamine agonists act like dopamine in the brain. Most of the agonists used until now mainly target two types of dopamine receptors, known as D2 and D3.

Tavapadon works differently. It selectively targets the D1 and D5 receptors, and AbbVie describes it as the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's. In plain language, it is a new way of working with the brain's dopamine system, which gives doctors another option when they tailor a treatment plan.

What the studies found

The approval was based on the Phase 3 TEMPO clinical trial program. TEMPO-1 and TEMPO-2 studied people with early Parkinson's who were not taking levodopa. TEMPO-3 studied people already on levodopa who were having "motor fluctuations," the ups and downs between times when symptoms are well controlled ("on" time) and times when they return ("off" time). Results have been published in peer-reviewed journals, including JAMA Neurology (TEMPO-1), The Lancet Neurology (TEMPO-2) and JAMA Neurology (TEMPO-3).

According to AbbVie's summary of the trials:

  • In people with early Parkinson's, tavapadon improved scores on everyday activities, such as dressing, eating and personal hygiene, compared with a placebo after 26 weeks. Combined scores that also measure motor skills improved as well.
  • In people already taking levodopa, adding tavapadon increased daily "on" time without troublesome dyskinesia (involuntary movements) by about 1.7 hours, compared with 0.6 hours for placebo. That finding comes from the TEMPO-3 trial.
  • Most side effects were mild or moderate. The most common included nausea, headache, dizziness and fatigue. Among people also taking levodopa, dyskinesia, hallucinations and a drop in blood pressure when standing were also reported.

Like other Parkinson's medicines, tavapadon carries important safety information, including the risk of low blood pressure, hallucinations, dyskinesia and unusual urges such as compulsive gambling or shopping. These are things to discuss openly with your care team before and during any treatment.

What the Parkinson's community is saying

The Michael J. Fox Foundation's chief scientist, Brian Fiske, PhD, was quoted in AbbVie's announcement: "Each therapy approval is an important milestone in building a diverse treatment pipeline needed to meet the full range of unmet needs across the Parkinson's community."

That is a helpful way to see this news. Tavapadon is not a cure, and it does not slow or stop the disease. What it adds is choice. Parkinson's affects every person differently, and more options can make it easier for doctors and families to find a plan that fits real life.

What this means for families in Miami and South Florida

If you or a loved one lives with Parkinson's, this approval may raise questions at your next appointment. A few that may help you prepare:

  • Could a medicine like this be an option for my stage of Parkinson's?
  • How would it fit with what I take now, including levodopa?
  • What side effects should my family and caregivers watch for?
  • Is it covered by my insurance, and what would it cost?

Please do not start, stop or change any medication on your own. Every treatment decision should be made with your neurologist or movement disorder specialist, who knows your full health history. Talk to your doctor about whether any new option is right for you.

A reason for hope

New approvals like this one are the result of years of research and of thousands of volunteers who joined clinical trials. Each one moves the field forward. At Rengifo Parkinson's Foundation, our mission is to educate people about Parkinson's disease and connect them with resources, so families in our community never have to face this news alone.

Want to learn more about our work? Visit our About page, read more on our Parkinson's blog, or support our mission with a donation on our Donate page, including by donating stock.

This article is for educational purposes only and is not medical advice. Talk to your doctor or neurologist about your care.

Sources: U.S. FDA; AbbVie; JAMA Neurology; The Lancet Neurology.

Leave a comment

Please note, comments must be approved before they are published